Verapamil Concentrations in Cerebrospinal Fluid after Oral Administration

Allen R. Doran, Prem K. Narang, Cynthia Y. Meigs, Owen M. Wolkowitz, Alec Roy, Alan Breier, David Pickar

Research output: Contribution to journalLetter

53 Scopus citations


To the Editor: Verapamil, a slow calcium-channel blocker widely used in medical practice, has recently been proposed as a treatment for psychiatric disorders, including depression and manic-depressive illness.1 The foundation for this proposal involves the role of intracellular calcium in the functioning of the neurotransmitter system2 3 4 and the ability of calcium antagonists to block these mechanisms in vitro.5 Despite reports of improvements in symptoms of migraine,6 the occurrence of central nervous system-like side effects, such as perceptual disorders7 and mood changes (Rosing D: personal communication), it is unknown to what extent verapamil is accessible to the central nervous system after.

Original languageEnglish (US)
Pages (from-to)1261-1262
Number of pages2
JournalNew England Journal of Medicine
Issue number19
StatePublished - May 9 1985
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Verapamil Concentrations in Cerebrospinal Fluid after Oral Administration'. Together they form a unique fingerprint.

  • Cite this

    Doran, A. R., Narang, P. K., Meigs, C. Y., Wolkowitz, O. M., Roy, A., Breier, A., & Pickar, D. (1985). Verapamil Concentrations in Cerebrospinal Fluid after Oral Administration. New England Journal of Medicine, 312(19), 1261-1262.